Anti-PD-L1 immunotherapy responsive in microsatellite-stable mCRC comb with MEK inhibition

Anti-PD-L1 immunotherapy may achieve a response in patients with microsatellite-stable metastatic colorectal cancer if combined with a MEK inhibitor, according to phase I data.